- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07948720
Dexmedetomidine as an Adjuvant to Bupivacaine in Fascia Iliaca Block for Femoral Fracture Surgery Under General Anesthesia: A Dose-Finding Study (FIB-DEX)
Dexmedetomidine Added to Bupivacaine in Fascia Iliaca Block Combined With General Anesthesia for Femoral Fracture Surgery: A Dose-Finding Randomized Double-Blind Study
### Brief Summary
Femoral fractures can cause severe pain during and after surgery. Although fascia iliaca block is commonly used to relieve pain in patients undergoing femoral fracture surgery, the duration of pain relief may be limited.
Dexmedetomidine is a medication that may prolong the pain-relieving effect of local anesthetics such as bupivacaine. However, the most appropriate dose of dexmedetomidine for this type of nerve block is not yet clearly established.
This study aims to determine the lowest effective dose of dexmedetomidine when added to bupivacaine for ultrasound-guided fascia iliaca block in patients undergoing femoral fracture surgery under general anesthesia.
The study includes 90 adult patients, aged 18-75 years, who are scheduled for femoral fracture surgery. Participants will be randomly assigned to one of three groups, with 30 patients in each group. All patients will receive general anesthesia and an ultrasound-guided fascia iliaca block containing 30 mL of 0.25% bupivacaine, combined with one of the following doses of dexmedetomidine:
- Group A: 0.5 micrograms/kg.
- Group B: 0.75 micrograms/kg.
- Group C: 1 microgram/kg.
Neither the patients nor the doctors assessing the study outcomes will know which dose has been administered.
Pain levels will be assessed during the first 24 hours after surgery using a numerical pain scale. The study will also measure the time until patients first require additional pain medication and the total amount of pain medication used.
Other assessments will include leg muscle strength, level of sedation, heart rate, blood pressure, and any possible side effects or complications.
The main purpose of this study is to identify the lowest dose of dexmedetomidine that provides effective postoperative pain relief while minimizing unwanted effects, helping improve pain management and recovery after femoral fracture surgery.
Panoramica dello studio
Stato
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Alaa Taha, MD
- Numero di telefono: +201276143115
- Email: Alaa.Taha@kasralainy.edu.eg
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Age between 18-75 years. both sexes. American Society of Anesthesiologists (ASA) physical status I-III Scheduled for femoral fracture surgery
Exclusion Criteria:
Allergy to study drugs. Heart block type II. Pre-existing neurologic or psychiatric disease. Severe hepatic or renal impairment. Infection at injection site.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: dexmedetomidine 0.5
Name: Dexmedetomidine 0.5 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 0.5 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia |
Intervention 1 - Group dexmeditomidine 0.5 Dexmedetomidine 0.5 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 0.5 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia. ---
Altri nomi:
|
|
Comparatore attivo: dexmedetomidine 0.75
Name: Dexmedetomidine 0.75 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 0.75 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia. |
Name: Dexmedetomidine 0.75 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 0.75 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia. |
|
Comparatore attivo: dexmedetomidine 1
Name: Dexmedetomidine 1 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 1 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesi |
Name: Dexmedetomidine 1 µg/kg with bupivacaine for supra-inguinal fascia iliaca block Description: Ultrasound-guided supra-inguinal fascia iliaca compartment block using 30 mL of 0.25% bupivacaine combined with dexmedetomidine 1 µg/kg, administered perineurally. The block is used as part of the perioperative analgesic regimen in patients undergoing femoral fracture surgery under general anesthesia. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Time to the first request for rescue analgesia in minutes
Lasso di tempo: from end of surgery to the first request for nalbuphine
|
time in minutes to first rescue analgesia will be measured. |
from end of surgery to the first request for nalbuphine
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
postoperative pain assessed as Numerical rating score (NRS)
Lasso di tempo: from 30 minutes after surgery to 24 hours after surgery
|
from 30 minutes after surgery to 24 hours after surgery
|
|
|
motor block using modified bromage scale
Lasso di tempo: from 30 minutes to 24 hours after surgery
|
from 30 minutes to 24 hours after surgery
|
|
|
total nalbuphine consumption in milligram (mg)
Lasso di tempo: from end of surgery to 24 hours after surgery
|
from end of surgery to 24 hours after surgery
|
|
|
heart rate
Lasso di tempo: starting before general anesthesia till 60 minutes after surgery
|
starting before general anesthesia till 60 minutes after surgery
|
|
|
sedation score
Lasso di tempo: from 30 minutes after the end of operations to 24 hours postoperative .
|
using ramsay sedation scale |
from 30 minutes after the end of operations to 24 hours postoperative .
|
|
mean arterial pressure
Lasso di tempo: starting before general anesthesia till 60 minutes after surgery
|
starting before general anesthesia till 60 minutes after surgery
|
|
|
systolic blood pressure
Lasso di tempo: starting before general anesthesia till 60 minutes after surgery
|
starting before general anesthesia till 60 minutes after surgery
|
|
|
diastolic blood pressure
Lasso di tempo: starting before general anesthesia till 60 minutes after surgery
|
starting before general anesthesia till 60 minutes after surgery
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- MS-228-2026
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .